CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,208 enrolled
Drug / intervention
Multivalent Group B streptococcus vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03765073
NCT03765073Phase 2Completed

A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS

Pfizer·interventional·Posted Dec 5, 2018·Updated Aug 5, 2025

In Brief

A Phase 2 clinical trial evaluating Multivalent Group B streptococcus vaccine and Placebo for Group B Streptococcus Infections. Completed, enrolled 1,208 participants across 35 sites in 3 countries.

Detailed Summary

Phase 1/2, randomized, placebo-controlled, observer-blinded study will evaluate the safety, tolerability and immunogenicity of the investigational multivalent group B streptococcus vaccine administered at one dose level (various formulations) in healthy nonpregnant women (various formulations at one dose level), and then in healthy pregnant women (various formulations at three dose levels), and finally in healthy pregnant women at a selected dose level/formulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Africa, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 5, 2018
Enrollment StartJan 14, 2019
Primary CompletionMar 4, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.6 years ago

Interventions

Multivalent Group B streptococcus vaccinebiological

Various formulations at three dose levels

Placebobiological

Saline control